Diagnostics News and Research

RSS

Merck Millipore announces joint development agreement with Sysmex Corporation

Merck Millipore, the Life Science division of Merck, today announced a clinical research, licensing and joint development agreement with Sysmex Corporation of Japan.

From Sysmex America, Inc. 18 Mar 2014

Trovagene reports net loss of $1 million for fourth quarter 2013

Trovagene, Inc., a developer of cell-free molecular diagnostics, today reported its financial results for the quarter and the year ended December 31, 2013.

18 Mar 2014

Researchers identify two novel genes associated with development of rare, aggressive blood cancer

Researchers have identified two novel cancer genes that are associated with the development of a rare, highly aggressive, cancer of blood vessels. These genes may now act as markers for future treatments and explain why narrowly targeted therapies that are directed at just one target fail.

17 Mar 2014

Six in every ten serious heart defects in foetuses go undetected in ultrasound scans

Over six in every ten serious heart defects in foetuses go undetected in the ultrasound scans given to all pregnant women. According to research at Linköping University in Sweden, one reason why malformations are not found is obesity in the expectant mother.

13 Mar 2014

Teenagers with autism spectrum disorder are more likely to wish to be another gender

Children and teenagers with an autism spectrum disorder or those who have attention deficit and hyperactivity problems are much more likely to wish to be another gender.

13 Mar 2014

GE announces winners of the GE Healthcare 2013 Cell Imaging Competition

GE Healthcare Life Sciences (NYSE:GE) today announced Vanessa Auld from Canada, Martin Barr from Ireland and Graham Wright from Singapore as the winners of the GE Healthcare 2013 Cell Imaging Competition.

12 Mar 2014

Three innovative tools to detect, test and initiate personalized drug treatment for seizures

A team of researchers from the National Institutes of Health, Emory University and Cedars-Sinai - specialists in identifying and treating very rare diseases - used three innovative tools to detect a previously unknown gene mutation, test potential therapies in the lab, and initiate personalized drug treatment for a boy with a lifelong history of uncontrollable seizures that caused significant impact on his cognitive and social development.

12 Mar 2014

Sysmex America, Henry Schein sign three-year distribution agreement

Sysmex America, Inc., a global leader in medical diagnostic testing equipment and information systems technology, and Henry Schein, Inc., the world's largest provider of health care products and services to office-based dental, animal health and medical practitioners, today announced the signing of a three-year distribution agreement between the companies effective immediately.

From Sysmex America, Inc. 11 Mar 2014

Exosome Diagnostics closes Series B financing round with the raising of $27 million

Exosome Diagnostics today announced the initial close of its Series B financing round with the raising of $27 million. Proceeds will be used to advance development of the Company's proprietary platform technology and commercial programs for non-invasive, fluid-based molecular diagnostics in oncology, neurodegenerative diseases and other clinical areas.

11 Mar 2014

Quest Diagnostics enters into definitive purchase agreement to acquire Summit Health

Quest Diagnostics, the world's leading provider of diagnostic information services, today announced that it has entered into a definitive purchase agreement under which Quest will acquire Summit Health.

From Quest Diagnostics 11 Mar 2014

Professors receive $31M grant to establish Center for Research in Diagnostics and Discovery

W. Ian Lipkin, director of the Center for Infection and Immunity and John Snow Professor of Epidemiology at the Mailman School of Public Health, has received an award of up to $31 million over a five-year period by the National Institutes of Health (NIH) to establish the Center for Research in Diagnostics and Discovery (CRDD) under the auspices of a new National Institute of Allergy and Infectious Diseases (NIAID) program entitled Centers of Excellence for Translational Research.

11 Mar 2014

Glycoprofiling test could halve number of false-positives in diagnosis of ovarian cancer

11 Mar 2014

New sugar-test may reduce false-positive ovarian cancer screening tests

The world's most widespread test for ovarian cancer reports false-positives in 94 of 100 diagnosed cases. Now, chemists at the University of Copenhagen working with clinical researchers at University College London have developed a method able to halve the number of false-positives. When fully developed, the new test will spare a significant number of women from unnecessary worry and further testing. Furthermore, global health care providers stand to save substantial sums - just by including a test on a certain sugar molecule in tandem with the currently prevailing diagnostic test.

10 Mar 2014

WuXi Genome Center buys Illumina HiSeq X Ten sequencing system

Illumina, Inc. and WuXi PharmaTech (Cayman) Inc., a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company with operations in China and the United States, today announced that the WuXi Genome Center has purchased an Illumina HiSeq X Ten sequencing system.

From Illumina, Inc. 10 Mar 2014

Nordion generates $70.8 million in revenue for first quarter of fiscal 2014

Nordion Inc., a leading provider of products and services to the global health science market, today reported results for the first quarter of fiscal 2014.

7 Mar 2014

Agendia co-founder to be honored with 2014 European Union Prize for Women Innovators

Agendia co-founder Laura van 't Veer, Ph.D., will receive a 2014 European Union Prize for Women Innovators in ceremonies next Monday. Dr. van 't Veer, of the Netherlands, is the inventor of Agendia's MammaPrint® breast cancer test.

7 Mar 2014

TAZ gene represents potential target for drug therapies to treat aggressive types of breast cancer

Significance: Understanding more about how the different types of cells in breast tissue develop improves our knowledge of breast cancer. TAZ represents a potential new target for drug therapies to treat aggressive types of breast cancer.

7 Mar 2014

Molecular subtyping determines breast cancer patients at high risk of disease recurrence

A method called molecular subtyping can help doctors better determine which of their breast cancer patients are at high risk of getting breast cancer again, a new study led by the University of South Florida reports.

7 Mar 2014

Boston Heart Diagnostics announces commercial launch of FDA-cleared MPO test

Boston Heart Diagnostics Corporation, a pioneer in integrating next-generation diagnostics into personalized nutrition and lifestyle programs for patients with or at risk for heart disease, announced the commercial launch of an FDA-cleared MPO (myeloperoxidase) test, a key biomarker for inflammation. Studies show that MPO levels are useful predictors of near-term (one to six months) risk of heart attack or stroke.

6 Mar 2014

Safeguard Scientifics reports net income of $24 million for fourth quarter 2013

Safeguard Scientifics, Inc. today announced fourth quarter and full-year 2013 financial results. For the three months ended December 31, 2013, Safeguard's net income was $24.0 million, or $1.10 per share, compared to net loss of $10.8 million, or $0.51 per share for the same period in 2012. For the year ended December 31, 2013, Safeguard's net loss was $35.5 million, or $1.66 per share, compared to $39.4 million, or $1.88 per share for the same period in 2012.

6 Mar 2014

Diagnostics News and Research

Merck Millipore announces joint development agreement with Sysmex Corporation

Trovagene reports net loss of $1 million for fourth quarter 2013

Researchers identify two novel genes associated with development of rare, aggressive blood cancer

Six in every ten serious heart defects in foetuses go undetected in ultrasound scans

Teenagers with autism spectrum disorder are more likely to wish to be another gender

GE announces winners of the GE Healthcare 2013 Cell Imaging Competition

Three innovative tools to detect, test and initiate personalized drug treatment for seizures

Sysmex America, Henry Schein sign three-year distribution agreement

Exosome Diagnostics closes Series B financing round with the raising of $27 million

Quest Diagnostics enters into definitive purchase agreement to acquire Summit Health

Professors receive $31M grant to establish Center for Research in Diagnostics and Discovery

Glycoprofiling test could halve number of false-positives in diagnosis of ovarian cancer

New sugar-test may reduce false-positive ovarian cancer screening tests

WuXi Genome Center buys Illumina HiSeq X Ten sequencing system

Nordion generates $70.8 million in revenue for first quarter of fiscal 2014

Agendia co-founder to be honored with 2014 European Union Prize for Women Innovators

TAZ gene represents potential target for drug therapies to treat aggressive types of breast cancer

Molecular subtyping determines breast cancer patients at high risk of disease recurrence

Boston Heart Diagnostics announces commercial launch of FDA-cleared MPO test

Safeguard Scientifics reports net income of $24 million for fourth quarter 2013

Event guide: 16th Clinical Biomarkers & CDx Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News